Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation [Seeking Alpha]
Arvinas, Inc. (ARVN)
Last arvinas, inc. earnings: 11/4 05:00 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
Arvinas entered into a strategic license agreement with Novartis for the development and commercialization of ARV-766, its second-generation PROTAC androgen receptor degrader for prostate cancer. Novartis is a force in prostate thanks to its recently-approved drug pluvicto, which has multi-billion peak revenue potential. As such, Arvinas may have found its perfect partner. There's plenty of risk involved in backing Arvinas - less so backing Novartis, a profitable global pharma - but I believe this deal can be win-win for both parties. Also, Arvinas has partnered with Pfizer for the development of vepdegestrant, receiving an upfront payment of $650 million and additional milestone payments which could exceed $1bn. Investment Overview - Arvinas's Shares Buoyant As Vepdegestrant / Ibrance Combo Study Initiated I covered the "protein degradation" specialist drug developer Arvinas ( NASDAQ: ARVN ) in a deep dive note for Seeking Alpha back in late November last year, giving the
Show less
Read more
Impact Snapshot
Event Time:
ARVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARVN alerts
High impacting Arvinas, Inc. news events
Weekly update
A roundup of the hottest topics
ARVN
News
- Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- Arvinas Appoints Randy Teel, Ph.D., as Chief Business OfficerGlobeNewswire
- Arvinas, Inc. (NASDAQ: ARVN) had its price target lowered by analysts at HC Wainwright from $90.00 to $87.00. They now have a "buy" rating on the stock.MarketBeat
- Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised [Yahoo! Finance]Yahoo! Finance
- UPDATE 1-Novartis licenses Arvinas' cancer drug for up to $1 billion [Yahoo! Finance]Yahoo! Finance
ARVN
Earnings
- 2/27/24 - Miss
ARVN
Sec Filings
- 4/17/24 - Form ARS
- 4/16/24 - Form DEFA14A
- 4/16/24 - Form DEF
- ARVN's page on the SEC website